Gavin Corcoran Net Worth

Gavin Corcoran biography

Dr. Gavin Corcoran M.D. serves as Chief Research and Development Officer of the Company. Prior to joining Axovant, he served as Chief Medical Officer of Allergan plc, a pharmaceutical company now part of Abbvie Inc., from March 2015 to June 2018 and of Actavis plc, a pharmaceutical company now part of Abbvie Inc., from July 2014 to March 2015. Dr. Corcoran served as Executive Vice President for Global Medicines Development at Forest Laboratories, a pharmaceutical company, from December 2011 to June 2014, prior to the acquisition of Forest Laboratories, Inc. by Actavis in 2014. Earlier in his career, Dr. Corcoran also served as Head of Late Stage Clinical Development for Inflammation and Immunology at Celgene Corporation, a pharmaceutical company, Chief Scientific Officer and head of R&D at Stiefel Laboratories, a dermatological pharmaceutical company, and he held various leadership roles in clinical development and regulatory affairs at Amgen Inc., Schering-Plough Corporation, and Bayer AG, each a pharmaceutical company. He received his M.B.B.Ch. from the University of the Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio.

What is the salary of Gavin Corcoran?

As the Chief Research and Development Officer of Axovant Gene Therapies, the total compensation of Gavin Corcoran at Axovant Gene Therapies is $1,457,260. There are 2 executives at Axovant Gene Therapies getting paid more, with Pavan Cheruvu having the highest compensation of $2,868,750.

How old is Gavin Corcoran?

Gavin Corcoran is 58, he's been the Chief Research and Development Officer of Axovant Gene Therapies since 2018. There are 3 older and 5 younger executives at Axovant Gene Therapies. The oldest executive at Axovant Gene Therapies Ltd. is Atul Pande, 66, who is the Lead Independent Director.

What's Gavin Corcoran's mailing address?

Gavin's mailing address filed with the SEC is 11 Times Square, New York, NY 10036, USA.

Insiders trading at Axovant Gene Therapies

Over the last 6 years, insiders at Axovant Gene Therapies have traded over $0 worth of Axovant Gene Therapies stock and bought 5,401,703 units worth $20,204,515 . The most active insiders traders include Sciences Ltd. Roivant, Andrew Lo, and Associates Gp Llcqvt Financ.... On average, Axovant Gene Therapies executives and independent directors trade stock every 65 days with the average trade being worth of $1,890,596. The most recent stock trade was executed by Atul Pande on 8 July 2020, trading 10,000 units of AXGT stock currently worth $27,300.

What does Axovant Gene Therapies do?

Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.

Axovant Gene Therapies executives and stock owners

Axovant Gene Therapies executives and other stock owners filed with the SEC include:

• Pavan Cheruvu,
  Chief Executive Officer, Director
• David Nassif,
  Principal Financial and Accounting Officer and General Counsel, Chief Financial Officer
• Gavin Corcoran,
  Chief Research and Development Officer
• Atul Pande,
  Lead Independent Director
• Frank Torti,
  Chairman of the Board
• Berndt Modig,
  Independent Director
• Senthil Sundaram,
  Independent Director
• Kristiina Vuori,
  Director
• Eric Venker,
  Director
• Parag Meswani,
  Chief Commercial Officer
• Sciences Ltd. Roivant,
  10% owner
• Investments (Uk) Ltd Soft B...,
  
• George Bickerstaff,
  Director
• Myrtle S Potter,
  Director
• Roger Jeffs,
  Director
• Associates Gp Llcqvt Financ...,
  
• Mathew C. Bazley,
  General Counsel
• Andrew Lo,